Published On: Mon, Jul 17th, 2017

Broker Changes For Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)


Recently stock market analysts have updated their consensus ratings on shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Most recent broker ratings

06/12/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 190 price target on the stock.

06/07/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 196 price target on the stock.

06/07/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 182 price target on the stock.

06/07/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 190 price target on the stock.

05/31/2017 – Jazz Pharmaceuticals plc had its “neutral” rating reiterated by analysts at Mizuho. They now have a USD 144 price target on the stock.

05/22/2017 – Jazz Pharmaceuticals plc had its “market perform” rating reiterated by analysts at Sanford C. Bernstein. They now have a USD 176 price target on the stock.

05/15/2017 – RBC Capital began new coverage on Jazz Pharmaceuticals plc giving the company a “outperform” rating. They now have a USD 210 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 170 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc was upgraded to “buy” by analysts at Janney Montgomery Scott. They now have a USD 175 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 197 price target on the stock.

03/01/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 190 price target on the stock.

02/22/2017 – Evercore ISI began new coverage on Jazz Pharmaceuticals plc giving the company a “buy” rating. They now have a USD 160 price target on the stock.

02/14/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 200 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at UBS. They now have a USD 168 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 200 price target on the stock.

Jazz Pharmaceuticals plc has a 50 day moving average of 151.80 and a 200 day moving average of 138.04. The stock’s market capitalization is 9.27B, it has a 52-week low of 95.80 and a 52-week high of 163.75.

The share price of the company (NASDAQ:JAZZ) was down -0.59% during the last trading session, with a high of 156.29 and the volume of Jazz Pharmaceuticals plc shares traded was 292353.